Immunogenicity of a promiscuous T cell epitope peptide based conjugate vaccine against benzo[a]pyrene: Redirecting antibodies to the hapten

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Schellenberger, Mario T ^a   Grova, Nathalie ^a   Farinelle, Sophie ^a   Willième, Stéphanie ^a   Revets, Dominique ^a   Muller, Claude P ^a  

^a LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

Author keywords

[No Author keywords available]

Indexed keywords

BENZO[A]PYRENE; EPITOPE; HAPTEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TETANUS TOXOID; ANTIBODY; PEPTIDE; VACCINE;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONJUGATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES; FEMALE; HELPER CELL; IMMUNOGENICITY; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; TISSUE DISTRIBUTION; AMINO ACID SEQUENCE; ANIMAL; ANTIBODY SPECIFICITY; CHEMISTRY; IMMUNIZATION; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; POLLUTANT; SYNTHESIS; TIME;

MUS;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES; ANTIBODY SPECIFICITY; BENZO(A)PYRENE; ENVIRONMENTAL POLLUTANTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, T-LYMPHOCYTE; FEMALE; HAPTENS; IMMUNIZATION; MICE; MOLECULAR SEQUENCE DATA; PEPTIDES; TETANUS TOXOID; TIME FACTORS; VACCINES, CONJUGATE;

EID: 84861636752     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038329     Document Type: Article

References (55)

1. Bostrom CE, Gerde P, Hanberg A, Jernstrom B, Johansson C, et al. (2002) Cancer risk assessment, indicators, and guidelines for polycyclic aromatic hydrocarbons in the ambient air. Environ Health Perspect 110 (Suppl 3): 451-488.
2. Thyssen J, Althoff J, Kimmerle G, Mohr U, (1981) Inhalation studies with benzo[a]pyrene in Syrian golden hamsters. J Natl Cancer Inst 66: 575-577.
3. Wolterbeek AP, Schoevers EJ, Rutten AA, Feron VJ, (1995) A critical appraisal of intratracheal instillation of benzo[a]pyrene to Syrian golden hamsters as a model in respiratory tract carcinogenesis. Cancer Lett 89: 107-116.
4. Carlson EA, Li Y, Zelikoff JT, (2004) Suppressive effects of benzo[a]pyrene upon fish immune function: evolutionarily conserved cellular mechanisms of immunotoxicity. Mar Environ Res 58: 731-734.
5. Davila DR, Romero DL, Burchiel SW, (1996) Human T cells are highly sensitive to suppression of mitogenesis by polycyclic aromatic hydrocarbons and this effect is differentially reversed by alpha-naphthoflavone. Toxicol Appl Pharmacol 139: 333-341.
6. Niu Q, Zhang H, Li X, Li M, (2009) Benzo[a]pyrene-induced neurobehavioral function and neurotransmitter alterations in coke oven workers. Occup Environ Med 67: 444-448.
7. Grova N, Schroeder H, Farinelle S, Prodhomme E, Valley A, et al. (2008) Sub-acute administration of benzo[a]pyrene (B[a]P) reduces anxiety-related behaviour in adult mice and modulates regional expression of N-methyl-d-aspartate (NMDA) receptors genes in relevant brain regions. Chemosphere 73: S295-302.
8. Sipinen V, Laubenthal J, Baumgartner A, Cemeli E, Linschooten JO, et al. (2010) In vitro evaluation of baseline and induced DNA damage in human sperm exposed to benzo[a]pyrene or its metabolite benzo[a]pyrene-7,8-diol-9,10-epoxide, using the comet assay. Mutagenesis 25: 417-425.
9. Younglai EV, Wu YJ, Foster WG, (2007) Reproductive toxicology of environmental toxicants: emerging issues and concerns. Curr Pharm Des 13: 3005-3019.
10. Perera F, (1981) Carcinogenicity of airborne fine particulate benzo(a)pyrene: an appraisal of the evidence and the need for control. Environ Health Perspect 42: 163-185.
11. Likhachev AJ, Beniashvili D, Bykov VJ, Dikun Tyndyk ML, et al. (1992) Relevance of quantitation of benzo(a)pyrene metabolites in animal excretes to evaluate individual human cancer risk. Prog Clin Biol Res 374: 435-452.
12. Hecht SS, (1998) Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chem Res Toxicol 11: 559-603.
13. Ross JA, Nelson GB, Wilson KH, Rabinowitz JR, Galati A, et al. (1995) Adenomas induced by polycyclic aromatic hydrocarbons in strain A/J mouse lung correlate with time-integrated DNA adduct levels. Cancer Res 55: 1039-1044.
14. McLemore TL, Martin RR, Wray NP, Cantrell ET, Busbee DL, (1978) Dissociation between aryl hydrocarbon hydroxylase activity in cultured pulmonary macrophages and blood lymphocytes from lung cancer patients. Cancer Res 38: 3805-3811.
15. Prough RA, Sipal Z, Jakobsson SW, (1977) Metabolism of benzo(a)pyrene by human lung microsomal fractions. Life Sci 21: 1629-1635.
16. Hecht SS, (1996) Carcinogen-Derived Biomarkers and Lung Cancer*1, *2. Preventive Medicine 25: 7-9.
17. Boysen G, Hecht SS, (2003) Analysis of DNA and protein adducts of benzo[a]pyrene in human tissues using structure-specific methods. Mutat Res 543: 17-30.
18. Hecht SS, (2001) Carcinogen biomarkers for lung or oral cancer chemoprevention trials. IARC Sci Publ 154: 245-255.
19. Hecht SS, (1996) Chemoprevention of lung cancer by isothiocyanates. Adv Exp Med Biol 401: 1-11.
20. Hainaut P, Pfeifer GP, (2001) Patterns of p53 G->T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis 22: 367-374.
21. Osada H, Takahashi T, (2002) Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer. Oncogene 21: 7421-7434.
22. De Buck SS, Augustijns P, Muller CP, (2005) Specific antibody modulates absorptive transport and metabolic activation of benzo[a]pyrene across Caco-2 monolayers. J Pharmacol Exp Ther 313: 640-646.
23. De Buck SS, Bouche FB, Brandenburger A, Muller CP, (2005) Modulation of the metabolism and adverse effects of benzo[a]pyrene by a specific antibody: a novel host factor in environmental carcinogenesis? Carcinogenesis 26: 835-844.
24. De Buck SS, Muller CP, (2005) Immunopropylactic approaches against chemical carcinogenesis. Vaccine 23: 2403-2406.
25. Grova N, Prodhomme EJ, Schellenberger MT, Farinelle S, Muller CP, (2009) Modulation of carcinogen bioavailability by immunisation with benzo[a]pyrene-conjugate vaccines. Vaccine 27: 4142-4151.
26. Schellenberger MT, Grova N, Willieme S, Farinelle S, Prodhomme EJ, et al. (2009) Modulation of Benzo[a]pyrene induced immunotoxicity in mice actively immunized with a B[a]P-diphtheria toxoid conjugate. Toxicol Appl Pharmacol.
27. Schellenberger MT, Farinelle S, Willieme S, Muller CP, (2011) Evaluation of adjuvants for a candidate conjugate vaccine against benzo[a]pyrene. Hum Vaccin 7 Suppl:pp. 166-173.
28. Keyler DE, Roiko SA, Earley CA, Murtaugh MP, Pentel PR, (2008) Enhanced immunogenicity of a bivalent nicotine vaccine. Int Immunopharmacol 8: 1589-1594.
29. Hatsukami DK, Rennard S, Jorenby D, Fiore M, Koopmeiners J, et al. (2005) Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther 78: 456-467.
30. Deng SX, de Prada P, Landry DW, (2002) Anticocaine catalytic antibodies. J Immunol Methods 269: 299-310.
31. Carrera MR, Ashley JA, Parsons LH, Wirsching P, Koob GF, et al. (1995) Suppression of psychoactive effects of cocaine by active immunization. Nature 378: 727-730.
32. Haney M, Gunderson EW, Jiang H, Collins ED, Foltin RW Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans. Biol Psychiatry 67: 59-65.
33. Polonelli L, Giovati L, Magliani W, Conti S, Sforza S, et al. (2011) Vaccination of lactating dairy cows for the prevention of aflatoxin B1 carry over in milk. PLoS One 6: e26777.
34. De Buck SS, Schellenberger MT, Ensch C, Muller CP, (2009) Effects of antibodies induced by a conjugate vaccine, on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone absorptive transport, metabolism and proliferation of human lung cells. Int J cancer.
35. Silbart LK, Rasmussen MV, Oliver AR, (1997) Immunoprophylactic intervention in chemical toxicity and carcinogenicity. Vet Hum Toxicol 39: 37-43.
36. Herzenberg LA, Tokuhisa T, (1980) Carrier-priming leads to hapten-specific suppression. Nature 285: 664-667.
37. Højrup P, (2003) Proteolytic Peptide Mapping pp. 227-244.
38. Prodhomme EJ, Fack F, Revets D, Pirrotte P, Kremer JR, et al. (2010) Extensive phosphorylation flanking the C-terminal functional domains of the measles virus nucleoprotein. J Proteome Res 9: 5598-5609.
39. Grova N, Valley A, Turner JD, Morel A, Muller CP, et al. (2007) Modulation of behavior and NMDA-R1 gene mRNA expression in adult female mice after sub-acute administration of benzo(a)pyrene. Neurotoxicology 28: 630-636.
40. Grova N, Feidt C, Laurent C, Rychen G, (2002) [14C] Milk, urine and faeces excretion kinetics in lactating goats after an oral administration of [14C]polycyclic aromatic hydrocarbons. International Dairy Journal 12: 1025-1031.
41. Ho PC, Mutch DA, Winkel KD, Saul AJ, Jones GL, et al. (1990) Identification of two promiscuous T cell epitopes from tetanus toxin. Eur J Immunol 20: 477-483.
42. Panina-Bordignon P, Tan A, Termijtelen A, Demotz S, Corradin G, et al. (1989) Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol 19: 2237-2242.
43. Demotz S, Lanzavecchia A, Eisel U, Niemann H, Widmann C, et al. (1989) Delineation of several DR-restricted tetanus toxin T cell epitopes. J Immunol 142: 394-402.
44. James EA, Bui J, Berger D, Huston L, Roti M, et al. (2007) Tetramer-guided epitope mapping reveals broad, individualized repertoires of tetanus toxin-specific CD4+ T cells and suggests HLA-based differences in epitope recognition. Int Immunol 19: 1291-1301.
45. Bouche FB, Steinmetz A, Yanagi Y, Muller CP, (2005) Induction of broadly neutralizing antibodies against measles virus mutants using a polyepitope vaccine strategy. Vaccine 23: 2074-2077.
46. Muller CP, Putz MM Peptide Vaccines: John Wiley & Sons, Ltd.
47. Putz MM, Ammerlaan W, Schneider F, Jung G, Muller CP, (2004) Humoral immune responses to a protective peptide-conjugate against measles after different prime-boost regimens. Vaccine 22: 4173-4182.
48. Lise LD, Mazier D, Jolivet M, Audibert F, Chedid L, et al. (1987) Enhanced epitopic response to a synthetic human malarial peptide by preimmunization with tetanus toxoid carrier. Infect Immun 55: 2658-2661.
49. Barington T, Gyhrs A, Kristensen K, Heilmann C, (1994) Opposite effects of actively and passively acquired immunity to the carrier on responses of human infants to a Haemophilus influenzae type b conjugate vaccine. Infect Immun 62: 9-14.
50. Granoff DM, Holmes SJ, Belshe RB, Osterholm MT, McHugh JE, et al. (1994) Effect of carrier protein priming on antibody responses to Haemophilus influenzae type b conjugate vaccines in infants. JAMA 272: 1116-1121.
51. Kurikka S, (1996) Priming with diphtheria-tetanus-pertussis vaccine enhances the response to the Haemophilus influenzae type b tetanus conjugate vaccine in infancy. Vaccine 14: 1239-1242.
52. Johansson AG, Lovdal T, Magnusson KE, Berg T, Skogh T, (1996) Liver cell uptake and degradation of soluble immunoglobulin G immune complexes in vivo and in vitro in rats. Hepatology 24: 169-175.
53. Skogh T, Blomhoff R, Eskild W, Berg T, (1985) Hepatic uptake of circulating IgG immune complexes. Immunology 55: 585-594.
54. Skogh T, Eskild W, Sundqvist T, Berg T, (1988) Elimination kinetics of circulating antigens and immune complexes. II. Hepatic and extrahepatic elimination of chemically modified albumin preparations in relation to their non-specific physicochemical properties. J Clin Lab Immunol 27: 13-17.
55. (2002) Polycyclic Aromatic Hydrocarbons - Occurrence in foods, dietary exposure and health effects. Food SCo, Directorate-General HaCP, editors: European Commission.